Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,578.03
-21.2968-1.33%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,598.74
Open:1,598.63
Low:1,570.99
Close:1,599.33
Volume:60.89M
Turnover:5.18B
Market Cap:1.64T
Float Cap:1.58T

Loading ...

Pfizer Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
2 hours ago

Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know

TradingKey
·
3 hours ago

Sector Update: Healthcare

MT Newswires Live
·
3 hours ago

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
4 hours ago

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
5 hours ago

Sector Update: Healthcare

MT Newswires Live
·
6 hours ago

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

TIPRANKS
·
6 hours ago

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
6 hours ago

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Dow Jones
·
7 hours ago

Pfizer Sued by Florida Attorney General Over Alleged Deceptive Marketing Practices

MT Newswires Live
·
Yesterday

Florida sues Pfizer over COVID vaccine marketing

TIPRANKS
·
Yesterday

Florida Attorney General: Files Lawsuit Against Pfizer and Its CEO Albert Bourla

THOMSON REUTERS
·
Yesterday

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing Nearly Half of Staff Layoffs

Dow Jones
·
Yesterday

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Yesterday

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Yesterday

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Yesterday

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Yesterday

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Yesterday